caa a22 4500 445808985 CHVBK 20180317145205.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s00415-010-5777-z doi (NATIONALLICENCE)springer-10.1007/s00415-010-5777-z BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis [Elektronische Daten] [D. MacManus, D. Miller, L. Kappos, R. Gold, E. Havrdova, V. Limmroth, C. Polman, K. Schmierer, T. Yousry, M. Eraksoy, E. Meluzinova, M. Dufek, M. Yang, G. O'Neill, K. Dawson] BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p<0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo. Springer-Verlag, 2010 Clinical trial nationallicence Multiple sclerosis nationallicence MRI nationallicence Dimethyl fumarate nationallicence BG-12 nationallicence Hypointense lesions nationallicence MacManus D. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut Miller D. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut Kappos L. Department of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland aut Gold R. University Clinic Bochum at St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany aut Havrdova E. Charles University in Prague, First Faculty of Medicine, Kateřinská 32, 121 08, Prague 2, Czech Republic aut Limmroth V. Cologne City Hospitals, University of Cologne, Ostmerheimer Str. 200, 51109, Cologne, Germany aut Polman C. VU Medical Centre, P. O. Box 7057, 1007 MB, Amsterdam, The Netherlands aut Schmierer K. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut Yousry T. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut Eraksoy M. Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey aut Meluzinova E. Department of Neurology, 2nd Medical School of Charles University, Motol University Hospital, Prague, Czech Republic aut Dufek M. Masaryk University, Žerotínovo nám. 617/9, 60177, Brno, Czech Republic aut Yang M. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut O'Neill G. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut Dawson K. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut Journal of Neurology Springer-Verlag 258/3(2011-03-01), 449-456 0340-5354 258:3<449 2011 258 415 https://doi.org/10.1007/s00415-010-5777-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-010-5777-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- MacManus D. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut NATIONALLICENCE 700 1- Miller D. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut NATIONALLICENCE 700 1- Kappos L. Department of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland aut NATIONALLICENCE 700 1- Gold R. University Clinic Bochum at St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany aut NATIONALLICENCE 700 1- Havrdova E. Charles University in Prague, First Faculty of Medicine, Kateřinská 32, 121 08, Prague 2, Czech Republic aut NATIONALLICENCE 700 1- Limmroth V. Cologne City Hospitals, University of Cologne, Ostmerheimer Str. 200, 51109, Cologne, Germany aut NATIONALLICENCE 700 1- Polman C. VU Medical Centre, P. O. Box 7057, 1007 MB, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Schmierer K. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut NATIONALLICENCE 700 1- Yousry T. NMR Research Unit, University College London Institute of Neurology, Queen Square, WCIN 3BG, London, UK aut NATIONALLICENCE 700 1- Eraksoy M. Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey aut NATIONALLICENCE 700 1- Meluzinova E. Department of Neurology, 2nd Medical School of Charles University, Motol University Hospital, Prague, Czech Republic aut NATIONALLICENCE 700 1- Dufek M. Masaryk University, Žerotínovo nám. 617/9, 60177, Brno, Czech Republic aut NATIONALLICENCE 700 1- Yang M. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut NATIONALLICENCE 700 1- O'Neill G. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut NATIONALLICENCE 700 1- Dawson K. Biogen Idec, Inc, 14 Cambridge Center, 02142, Cambridge, MA, USA aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/3(2011-03-01), 449-456 0340-5354 258:3<449 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer